Cargando…

Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis

We evaluated the incidence of pseudoprogression and indeterminate response (IR) in patients with lymphoma treated with immune checkpoint inhibitors (ICIs). A systematic search of PubMed and EMBASE was performed up to 6 February 2021, using the keywords “lymphoma,” “immunotherapy,” and “pseudoprogres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Amy Junghyun, Kim, Kyung Won, Cho, Young Chul, Ko, Yousun, Sung, Yu Sub, Shin, Youngbin, Lee, Jiwoo, Kim, Mi-hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197164/ https://www.ncbi.nlm.nih.gov/pubmed/34071024 http://dx.doi.org/10.3390/jcm10112257

Ejemplares similares

Comprehensive Analysis for Anti-Cancer Target-Indication Prioritization of Placental Growth Factor Inhibitor (PGF) by Use of Omics and Patient Survival Data
por: Kim, Nari, et al.
Publicado: (2023)

A reliable and robust method for the upper thigh muscle quantification on computed tomography: toward a quantitative biomarker for sarcopenia
por: Ko, Yousun, et al.
Publicado: (2022)

Development and validation of an ensemble artificial intelligence model for comprehensive imaging quality check to classify body parts and contrast enhancement
por: Na, Seongwon, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
por: Urban, Hans, et al.
Publicado: (2022)

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
por: Won, Sang Eun, et al.
Publicado: (2020)

A Good Practice–Compliant Clinical Trial Imaging Management System for Multicenter Clinical Trials: Development and Validation Study
por: Shin, Youngbin, et al.
Publicado: (2019)

Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence
por: Kim, Nari, et al.
Publicado: (2022)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
por: Mönch, Sebastian, et al.
Publicado: (2023)

Development of a fully automatic deep learning system for L3 selection and body composition assessment on computed tomography
por: Ha, Jiyeon, et al.
Publicado: (2021)

Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
por: Zhu, Wanshan, et al.
Publicado: (2023)

Pushing the limits of immune-related response: a case of “extreme pseudoprogression”
por: Wong, Alvin S., et al.
Publicado: (2018)

Simultaneous Pseudoprogression and an Immune-related Adverse Event of Pulmonary Pleomorphic Carcinoma after Combined Therapy with Cytotoxic Anticancer Agents and Immune Checkpoint Inhibitor
por: Murao, Koutaro, et al.
Publicado: (2022)

Assessment of Myosteatosis on Computed Tomography by Automatic Generation of a Muscle Quality Map Using a Web-Based Toolkit: Feasibility Study
por: Kim, Dong Wook, et al.
Publicado: (2020)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
por: Shin, Min Hwa, et al.
Publicado: (2020)

Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
por: Choi, Changhoon, et al.
Publicado: (2019)

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma
por: Lee, Hyunjee, et al.
Publicado: (2023)

Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
por: Lee, Seon-Mi, et al.
Publicado: (2023)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators
por: Byun, Hwa Kyung, et al.
Publicado: (2021)

Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors
por: Kim, Hye Ryeon, et al.
Publicado: (2022)

Machine Learning Approaches for Assessing Risk Factors of Adrenal Insufficiency in Patients Undergoing Immune Checkpoint Inhibitor Therapy
por: Kim, Woorim, et al.
Publicado: (2023)

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

True Progression versus Pseudoprogression in the Treatment of Glioblastomas: A Comparison Study of Normalized Cerebral Blood Volume and Apparent Diffusion Coefficient by Histogram Analysis
por: Song, Yong Sub, et al.
Publicado: (2013)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021)

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
por: Lin, Adam Yuh, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

Pseudoprogression in low-grade glioma
por: Slater, Jason M., et al.
Publicado: (2019)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
por: Lee, Won Suk, et al.
Publicado: (2020)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
por: Lee, Juwon, et al.
Publicado: (2021)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
por: Kim, Eun Young, et al.
Publicado: (2019)

Metabolic activity of extranodal NK/T cell lymphoma on (18)F-FDG PET/CT according to immune subtyping
por: Lim, Chae Hong, et al.
Publicado: (2021)

Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment
por: Kim, Jehun, et al.
Publicado: (2022)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_edop2q1m8sslbcmohl1f1puinl